Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Proton Beam Therapy Doses with Chemotherapy in Unresectable Stage 2/3 NSCLC
NCT03132532Phase 2Completed
- Sponsor
- Mayo Clinic
- Start
- Jul 2017
- Primary completion
- Dec 2023
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of carboplatin, cisplatin, etoposide, paclitaxel and pemetrexed in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Mayo Clinic. Primary endpoint: Progression-Free Survival at 5 years. Started Jul 2017; status: completed.
02
Drugs
carboplatincisplatinetoposidepaclitaxelpemetrexed
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03132532.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03132532.